Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism ...

The immunology alliance follows a collaboration between the UK Biobank and the University of Exeter, supported by the Novo ...

Swiss biotech Nouscom has closed a €120 million ($135 million) fourth-round financing for a vaccine to protect people with a ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight management and treatment of type 2 diabetes (T2D). The decision puts ...

GSK is preparing to cut more than 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels, according to national newspaper L'Echo. The article notes ...

Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight. From temperature monitoring devices and connected containers ...

According to an update on the clinicaltrials.gov registry website, Novartis has terminated the study of Fabhalta (iptacopan) ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff came ...

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...